InflaRx Raises Financing to Develop a New Therapeutic Approach against Sepsis

JENA, Germany--()--InflaRx GmbH, announced today the closing of its seed financing led by Affentranger Associates alongside with bm-t beteiligungsmanagement thüringen gmbh. InflaRxs mission is to develop new therapeutic approaches to prevent and treat sepsis. Created by Prof. Niels Riedemann and Prof Renfeng Guo, two worldwide recognized researchers in the field of inflammation and sepsis, InflaRx has already brought its leading development program targeting activation products of the complement system in an advanced pre-clinical stage.

Aware of many targets which have failed in the past, we are developing a new breakthrough approach to address the sepsis indication by combining our state of the art R&D program with the worldwide recognized clinical sepsis research center in Jena says Prof. Niels Riedemann CEO of InflaRx. The high potential of InflaRx of addressing a critical unmet medical need with a new very promising target and a clear clinical strategy has been recognized by the seed investor group adds Nicolas Fulpius, Chairman of the board of InflaRx and Partner at Affentranger Associates. The competence of InflaRx will create strong synergies for Jena as fast growing center of sepsis expertise underlines. Dr. Guido Bohnenkamp, Managing Director of bm-t.

As of today, sepsis - also called blood poisoning in the public press - is the most frequent cause of death in non-cardiological intensive care units worldwide. With over 1.5 million cases in Europe and North America alone, and with mortality rates up to 50%, sepsis remains one of the largest and least publicly recognized unmet medical needs.

Based in Jena (Germany), a worldwide recognized sepsis research hub , InflaRx is developing its innovative therapeutic programs in cooperation with the University Hospital of the Friedrich Schiller University in Jena, the University of Michigan in USA and Beijing Mabworks Biotech Co., LTD in China. The Scientific Advisory Board of InflaRx is composed by two world leaders in the field of basic sepsis research with Prof P. Ward at the University of Michigan and clinical sepsis research with Prof. K. Reinhart at the Friedrich-Schiller-University in Jena.

About Affentranger Associates SA

Incorporated in 2002, Affentranger Associates is a Switzerland based business platform focused on the theme of value creation and active management. As principal investor, the company has the ambition to achieve sustainable long-term returns by investing with a combination of management and capital in high-growth potential companies. Affentranger Associates has offices in Geneva and Zurich.

About bm-t beteiligungsmanagement thüringen gmbh

The bm-t, a daughter company of the Thüringer Aufbaubank, acts as the management company of four Thüringen dedicated investment funds, the TI - Thüringer Innovationsfonds, VCT Venture Capital Thüringen, TIB - Thüringer Industriebeteiligungs and the PET - Private Equity Thüringen. As of today, the bm-t manages a portfolio of more than 40 companies located in Thüringen (Germany) for a total of more than EURO 165M under management.

Contacts

InflaRx GmbH
Prof. Dr. Niels C. Riedemann, +49-3641-508-180
or
Affentranger Associates SA
Nicolas Fulpius, +41-228-180-180
www.aasa.com
or
bm-t Beteiligungsmanagement GmbH & Co. KG
Dr. Guido Bohnenkamp, +49-361-7447-600
www.bm-t.com

Contacts

InflaRx GmbH
Prof. Dr. Niels C. Riedemann, +49-3641-508-180
or
Affentranger Associates SA
Nicolas Fulpius, +41-228-180-180
www.aasa.com
or
bm-t Beteiligungsmanagement GmbH & Co. KG
Dr. Guido Bohnenkamp, +49-361-7447-600
www.bm-t.com